Mutual of America Capital Management LLC lowered its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 49.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 25,270 shares of the company's stock after selling 25,071 shares during the period. Mutual of America Capital Management LLC's holdings in Vaxcyte were worth $2,069,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC purchased a new stake in Vaxcyte in the 4th quarter valued at $28,000. Blue Trust Inc. raised its stake in Vaxcyte by 100.0% during the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after purchasing an additional 371 shares during the period. Meeder Asset Management Inc. boosted its holdings in Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock valued at $80,000 after purchasing an additional 635 shares during the last quarter. Nomura Asset Management Co. Ltd. purchased a new stake in shares of Vaxcyte in the 3rd quarter valued at approximately $92,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Vaxcyte during the 4th quarter worth approximately $161,000. Institutional investors and hedge funds own 96.78% of the company's stock.
Insiders Place Their Bets
In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total value of $710,240.00. Following the sale, the chief financial officer now directly owns 109,491 shares of the company's stock, valued at approximately $9,720,610.98. This trade represents a 6.81 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Teri Loxam sold 6,250 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the transaction, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,250 shares of company stock worth $4,550,258. Company insiders own 3.10% of the company's stock.
Analyst Upgrades and Downgrades
PCVX has been the subject of several analyst reports. The Goldman Sachs Group began coverage on Vaxcyte in a research report on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective for the company. Guggenheim restated a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, February 26th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte currently has a consensus rating of "Buy" and an average price target of $147.50.
View Our Latest Report on Vaxcyte
Vaxcyte Stock Up 1.4 %
PCVX traded up $0.96 on Tuesday, reaching $69.85. The company had a trading volume of 973,108 shares, compared to its average volume of 1,189,999. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06. The stock has a market capitalization of $8.99 billion, a PE ratio of -15.18 and a beta of 1.02. The stock has a 50-day moving average price of $83.06 and a 200-day moving average price of $94.66.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of ($1.16) by $0.14. As a group, analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.
About Vaxcyte
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
See Also
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
